Pharmacogenetic considerations in the treatment of psychiatric disorders

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 423-439

  Lohoff, Falk W ^a   Ferraro, Thomas N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse events; Genetics; Personalized medicine; Pharmacogenomics; Pharmacology; Psychiatric disorders; Treatment response

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DEBRISOQUINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PHENYTOIN; PLACEBO; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALLELE; ANXIETY DISORDER; APLASTIC ANEMIA; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; DISEASE PREDISPOSITION; DROWSINESS; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPILEPSY; ERECTILE DYSFUNCTION; ETHNICITY; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMPULSE CONTROL DISORDER; LIBIDO DISORDER; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; METABOLIC DISORDER; MOLECULAR CLONING; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; ORGASM DISORDER; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; REMISSION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STOMACH DISCOMFORT; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BRAIN; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DYSKINESIA, DRUG-INDUCED; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMICS; GENOTYPE; HUMANS; MEDICATION ADHERENCE; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS;

EID: 76449099134     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903508762     Document Type: Review

References (185)

1. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 2008;18(3):157-169
2. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112(2):457-473
3. Schonfeld WH, Verboncoeur CJ, Fifer SK, et al. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord 1997;43(2):105-119
4. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617-627 (Pubitemid 40973437)
5. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16(4):162-171
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163(1):28-40
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163(11):1905-1917
8. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006;38(2):82-94
9. Serretti A, Artioli P. From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl) 2004;174(4):490-503
10. Ebinger M, Uhr M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 2006;256(5):294-298
11. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002;162(1):18-23
12. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006;7:223-245
13. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278(1):441-446
14. Gaedigk A, Ndjountche L, Divakaran K, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007;81(2):242-251
15. Dalen P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63(4):444-452
16. Schenk PW, van Fessem MA, Verploegh-Van Rij S, et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2007;13:597-605
17. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53(2):111-122
18. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003;25(6):738-742
19. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000;22(2):202-208
20. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31(5):493-502
21. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14(4):230-240
22. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008;30(4):474-482
23. Alvares AP, Pantuck EJ, Anderson KE, et al. Regulation of drug metabolism in man by environmental factors. Drug Metab Rev 1979;9(2):185-205
24. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (NY) 1996;274(5292):1527-1531
25. Gelernter J, Cubells JF, Kidd JR, et al. Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet 1999;88(1):61-66
26. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1074-1084
27. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2008;150B:341-351
28. Baune BT, Hohoff C, Mortensen LS, et al. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect? Depress Anxiety 2008;25(11):920-925
29. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007;12(3):247-257
30. Perlis RH. Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am 2007;30(1):125-138
31. Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008;9(7):935-946
32. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25(1):119-142 (Pubitemid 38230109)
33. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78(5):804-814
34. Strome EM, Clark CM, Zis AP, Doudet DJ. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F] setoperone. Biol Psychiatry 2005;57(9):1004-1010
35. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7(5):541-547
36. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008;63:1103-1110
37. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007;164(8):1181-1188
38. Kraft JB, Peters EJ, Slager SL, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61(6):734-742
39. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007;64(7):783-792
40. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164(10):1530-1538
41. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007;64(6):689-697
42. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of general psychiatry 2009;66(9):966-975
43. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008;8(2):90-100
44. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008;38(2):289-300
45. Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009;9(4):225-233
46. MurphyGM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160(10):1830-1835
47. Murphy GM, Jr., Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61(11):1163-1169
48. Smits K, Smits L, Peeters F, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007;22(3):137-143
49. Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009;34(7):1819-1828
50. FDA. US Food and Drug Administration: FDA public health advisory: suicidality in children and adolescents being treated with antidepressant medications. Available from: http://www.fda.gov/cder/drug/ antidepressants/ SSRIPHA200410.htm. [Last accessed 15 October 2004]
51. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292(3):338-343
52. Licinio J, Wong ML. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev 2005;4(2):165-171
53. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-1363
54. Perlis RH, Holt DJ, Smoller JW, et al. Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants. Arch Gen Psychiatry 2008;65(8):882-892
55. Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP Project. Neuropsychopharmacology 2009;34:2517-2528
56. Henderson DC. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J Clin Psychiatry 2008;69(2):e04
57. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007;33(3):169-175
58. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002;63(Suppl 9):25-29
59. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry 2006;163(8):1316-1318
60. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209- 1223
61. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10(1):79-104
62. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22
63. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12(8):707-747
64. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9(5):410-418
65. Kirchheiner J, Lang U, Stamm T, et al. Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol 2006;26(4):440-442
66. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44(5):439-446
67. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276(2):658-666
68. Murayama N, Soyama A, Saito Y, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308(1):300-306
69. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-449
70. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001;21(6):603-607
71. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24(2):214-219
72. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005;27(4):539-543
73. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68(Suppl 6):5-9
74. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703-1711
75. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10(1):27-39
76. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157(4):514-520
77. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161(5):818-825
78. Himei A, Koh J, Sakai J, et al. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/ Del polymorphisms. Psychiatry Clin Neurosci 2002;56(1):97-102
79. Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005;376(1):1-4
80. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006;163(3):529-531
81. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4(3):290-296
82. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225(3):1068-1072
83. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999;10(1):17-20
84. Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;124B(1):1-5
85. Joober R, Toulouse A, Benkelfat C, et al. DRD3 and DAT1 genes in schizophrenia: an association study. J Psychiatr Res 2000;34(4-5):285-291
86. Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005;15(2):143-151
87. Meltzer HY, Gudelsky GA. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittelforschung 1992;42(2A):268-272
88. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346(8970):281-282
89. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32(2):93-99
90. Lin CH, Tsai SJ, Yu YW, et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999;10(1):57-60
91. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999;24(2):141-146
92. Yu YW, Tsai SJ, Yang KH, et al. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 2001;43(2):79-82
93. Lane HY, Chang YC, Chiu CC, et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002;159(9):1593-1595
94. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996;217(2-3):177-178
95. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19(2):123-132
96. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89(1-3):91-100
97. Wehmeier PM, Gebhardt S, Schmidtke J, et al. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005;133(2-3):273-276
98. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005;15(4):285-289
99. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B(1):76-78
100. Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B(1):97-100
101. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and genomics 2005 15(4):195-200
102. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol 2006;20(Suppl 4):15-18
103. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160(4):677-679
104. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359(9323):2086-2087
105. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006;7(6):863-887
106. Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004;4(2):77-87
107. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44(2):95-98
108. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2(2):139-145
109. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4(3):247-253
110. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27(1):105-119
111. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006;83(2-3):185-192
112. Munro J, O'sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576-580
113. Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998;1(1):41-44
114. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007;7(5):325-332
115. Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001;11(2):135-141
116. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47(10):945-948
117. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998;25(1):11-13
118. Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother 2007;7(1):9-16
119. Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology 2006;67(11):1916-1925
120. Post RM, Denicoff KD, Frye MA, et al. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998;38(3):152-166
121. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav 2005;7(1):18-36
122. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007;32(4):333-341
123. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2(10):349-352
124. Schou M. Preventive lithium treatment in manic-depressive disease: experiences and progress in recent years. Der Nervenarzt 1983;54(7):331-339
125. Lohoff FW, Berrettini WH. Genetics of Mood Disorders. In: Charney D, Nestler E, editors, Neurobiology of mental illness. 3rd edition. Oxford University Press; 2008. p. 1504
126. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11(7):999-1029
127. Mendlewicz J, Fieve RR, Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 1973;130(9):1011-1013
128. Grof P, Alda M, Grof E, et al. Lithium response and genetics of affective disorders. J Affect Disord 1994;32(2):85-95
129. Prien RF, Caffey EM, Jr., Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974;31(2):189-192
130. Smeraldi E, Petroccione A, Gasperini M, et al. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J Affect Disord 1984;6(2):139-151
131. Morissette J, Villeneuve A, Bordeleau L, et al. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 1999;88(5):567-587
132. Turecki G, Grof P, Grof E, et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 2001;6(5):570-578
133. Coyle JT, Manji HK. Getting balance: drugs for bipolar disorder share target. Nat Med 2002;8(6):557-558
134. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59(3):411-419
135. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93(16):8455-8459
136. Benedetti F, Serretti A, Pontiggia A, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 2005;376(1):51-55
137. Benedetti F, Bernasconi A, Lorenzi C, et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004;355(1-2):37-40 (Pubitemid 38077179)
138. Szczepankiewicz A, Rybakowski JK, Suwalska A, et al. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry 2006;7(3):158-161
139. Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 2007;62(11):1295-1302
140. Serretti A, Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms. Am J Pharmacogenomics 2003;3(1):17-30
141. Mamdani F, Groisman IJ, Alda M, Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J 2004;4(3):161-170
142. Serretti A, Lorenzi C, Lilli R, et al. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet 2002;114(4):370-379
143. Serretti A, Lilli R, Lorenzi C, et al. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res 1999;87(1):7-19 (Pubitemid 29421694)
144. Serretti A, Lorenzi C, Lilli R, Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000;34(2):89-98 (Pubitemid 30176115)
145. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40
146. Bremer T, Diamond C, McKinney R, et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagn Ther 2007;11(3):161-170
147. Cavazzoni P, Alda M, Turecki G, et al. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996;64(2):91-96 (Pubitemid 26344770)
148. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008;9(11):1595-1603
149. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol Rep 2005;57(6):761-765
150. Duffy A, Turecki G, Grof P, et al. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci 2000;25(4):353-358
151. Mamdani F, Alda M, Grof P, et al. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008;147B(4):500-504
152. Masoliver E, Menoyo A, Perez V, et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr Genet 2006;16(1):25-29
153. Masui T, Hashimoto R, Kusumi I, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006;9(1):83-88
154. Masui T, Hashimoto R, Kusumi I, et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr Genet 2006;16(2):49-50
155. Masui T, Hashimoto R, Kusumi I, et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):204-208
156. Michelon L, Meira-Lima I, Cordeiro Q, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006;403(3):288-293
157. Rybakowski JK, Suwalska A, Czerski PM, et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005;57(1):124-127
158. Rybakowski JK, Suwalska A, Skibinska M, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005;38(4):166-170 (Pubitemid 41059223)
159. Serretti A, Lilli R, Lorenzi C, et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 1999;33(5):371-377
160. Serretti A, Lilli R, Mandelli L, et al. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001;1(1):71-77
161. Serretti A, Malitas PN, Mandelli L, et al. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J 2004;4(4):267-273
162. Squassina A, Congiu D, Manconi F, et al. The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res 2008;57(5):369-373
163. Turecki G, Alda M, Grof P, et al. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Res 1996 63(1):17-23 (Pubitemid 26228644)
164. Zill P, Malitas PN, Bondy B, et al. Analysis of polymorphisms in the alpha-subunit of the olfactory G-protein Golf in lithium-treated bipolar patients. Psychiatr Genet 2003;13(2):65-69
165. Baum AE, Akula N, Cabanero M, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008;13(2):197-207
166. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64(7):1134-1138
167. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353(9171):2190-2194
168. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49(2):542-546
169. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129(1):92-96
170. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486
171. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16(4):297-306
172. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48(5):1015-1018
173. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49(12):2087-2091
174. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18(2):99-107
175. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7(6):813-818
176. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6(4):265-268
177. Ferrell PB, Jr., McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9(10):1543-1546
178. FDA. Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements (2008). Available from: http://www.fda. gov/medwatch/safety/2007/ safety07. htm#carbamazepine. 2007 [Cited]
179. Willett WC. Balancing life-style and genomics research for disease prevention. Science (NY) 2002;296(5568):695-698
180. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008;42(10):791-796
181. Montgomery SA. Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999;9(3):265-269
182. Charney DS, Nemeroff CB, Lewis L, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002;59(3):262-270
183. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47(1):75-85
184. Mrazek DA. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice. CNS Spectr 2006;11(3 Suppl 3):3-4
185. Katsanis SH, Javitt G, Hudson K. Public health. A case study of personalized medicine. Science (NY) 2008;320(5872):53-54